Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Ssr Mining Signs $464M M&A Deal with Roxmore Resources Inc.
SSR Mining has entered into a definitive agreement to acquire all outstanding shares of Roxmore Resources for C$6.75 per share in cash, representing a total equity value of approximately $464 million. The deal includes Roxmore's Converse Gold Project in Nevada, which SSR Mining plans to develop as a contiguous asset to its Marigold Complex to capture over $200 million in synergies. As part of the transaction, Roxmore will spin off its non-core exploration assets into a new company, SpinCo, in which SSR Mining will retain a 14.99% interest.
bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.
Cohen & Steers Income Opportunities REIT M&A Deal with Manchester Village
Cohen & Steers Income Opportunities REIT, Inc. (CNSREIT) has acquired Manchester Village, a 99%-occupied community shopping center in Rock Hill, South Carolina. The acquisition was made through a programmatic joint venture with the Sterling Organization and aligns with the REIT's strategy of investing in necessity-based retail in high-growth submarkets of the Charlotte metropolitan area.
Sizzle Acquisition Corp. II M&A Deal with Trasteel Holding S.A.
Sizzle Acquisition Corp. II provided a status update on its pending business combination with Trasteel Holding S.A. by furnishing Trasteel's first half 2026 financial results. Trasteel reported H1 2026 revenues of $1.19 billion and EBITDA of $50.7 million, while reaffirming its full-year 2026 revenue guidance of $2.1-$2.5 billion.
Bumble Inc. has entered into a definitive agreement to be acquired by Ithaca Holdings in an all-cash transaction valuing the company at $1.3 billion. Under the terms of the deal, Class A shareholders will receive $6.05 per share, representing a 138% premium to the unaffected closing price. Upon completion, Bumble will become a privately-held company and Ithaca Co-CEOs Ravi Gupta and John Hegeman will lead the company alongside founder Whitney Wolfe Herd.
Ondas is scaling rapidly through an integrated 'One Ondas' platform, raising 2026 revenue guidance significantly while leveraging a massive $757 million backlog and $11 billion pipeline.
Workday has entered into a definitive agreement to acquire C1.ai, a leading agentic identity platform for people and AI agents. The acquisition aims to integrate identity governance directly into Workday's core platform to manage real-time access for humans and autonomous agents across enterprise systems. The transaction is subject to customary closing conditions.
Ondas Inc. and Palantir have launched Regna AI, a new standalone company and strategic partnership focused on providing sovereign AI solutions for defense and government sectors. Regna AI will utilize Palantir's AIP platform and Ondas' expertise in autonomous systems to deploy fine-tuned open-weight models that allow governments to maintain control over their mission data and AI models.
CervoMed announced positive initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed a mean reduction in plasma neurofilament light chain (NfL) levels, a key marker of neurodegeneration, which contrasts with the increases typically seen in the natural history of the disease.
SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.
First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.
Horizon Space Acquisition I Signs $2B M&A Deal with ArcheNova Biotech Corp.
Horizon Space Acquisition I Corp. (HSPO), a SPAC, has entered into a definitive business combination agreement with clinical-stage biopharmaceutical company ArcheNova Biotech Corp. The transaction values ArcheNova at an implied enterprise value of $2.0 billion. Upon closing, the combined entity, ArcheNova Technology Co., Ltd, is expected to list on the Nasdaq Stock Market.
Eightco Holdings Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on August 5, 2026, and Nasdaq has now officially closed the matter.
Newton Golf Company received a Staff Determination letter from Nasdaq on October 6, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders’ equity requirement. As a result, the company's common stock faces suspension and delisting unless it successfully appeals the decision. The company intends to request a hearing before a Nasdaq Hearings Panel to stay the suspension and seek continued listing.
iBio released preclinical body-composition data from an eight-week obese non-human primate (NHP) study of its Activin E antibody candidate, IBIO-610. The study demonstrated that combining IBIO-610 with semaglutide resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone, suggesting significant muscle preservation potential. The company plans to initiate first-in-human clinical trials in the first half of 2027.
Skydance M&A Deal with Warner Bros. Discovery, Inc.
Skydance Corporation (formerly Paramount Skydance Corporation) completed its acquisition of Warner Bros. Discovery, Inc. (WBD) on October 6, 2026. In connection with the closing, the company is executing exchange and tender offers for WBD's outstanding senior notes and distributed warrants to its Class B stockholders as a dividend.
Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.
GigCapital8 Corp. has entered into a definitive merger agreement to acquire Quantisimo Corp. through a multi-step merger process involving a new holding company, Quantisimo Holdings Corp. (PubCo). As part of the transaction, WISeQey and SealSQ will contribute their equity interests in several operating subsidiaries, including Miraex SA and SEALCOIN AG, to Quantisimo prior to the closing.
Strategy Inc raised $21.0 million in net proceeds through the sale of 125,183 shares of Class A Common Stock under its at-the-market (ATM) offering program between October 5 and October 11, 2026. The proceeds were used to fund the acquisition of 250 bitcoin, bringing the company's total holdings to 848,250 BTC. Additionally, the company repurchased $192.4 million of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) during the same period.
Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.
Iron Horse Acquisition II Corp. (IRHO) provided a status update regarding its pending merger with Electra Vehicles, Inc. (ELECTRA AI) by announcing a new three-year partnership between Electra and Westbrook Racing. Electra has been selected as the Official Battery Intelligence Partner for the racing team, deploying its AI Brain for Batteries platform starting with the 2026 UIM E1 World Championship season.
Innventure's subsidiary, Accelsius, upgraded its Springdale facility in Austin, Texas, to multi-megawatt power capacity to test next-generation AI liquid cooling systems at megawatt-class rack densities. The company also announced it will expand its lease footprint at the facility by 18,000 square feet in January 2027 to support hyperscale customer validation programs.
Kenvue Signs $7B M&A Deal with Kimberly-Clark Corporation
Kenvue Inc. entered into a supplemental indenture to amend existing senior notes in connection with its pending acquisition by Kimberly-Clark Corporation. The amendments, which eliminate restrictive covenants and reporting requirements, are tied to an exchange offer where Kimberly-Clark will issue up to $7 billion in new notes to replace Kenvue's existing debt.
Kimberly Clark Signs $7B M&A Deal with Kenvue Inc.
Kimberly-Clark announced the early tender results of its offers to exchange up to $7.0 billion of Kenvue Inc. notes for new Kimberly-Clark notes and cash. The exchange offers and related consent solicitations are part of Kimberly-Clark's previously announced pending acquisition of Kenvue. The requisite consents were received to amend the Kenvue indenture, with the acquisition expected to close in the fourth quarter of 2026.
Getty Images entered into a restructuring support agreement (RSA) to implement a comprehensive recapitalization through a prepackaged Chapter 11 plan of reorganization. The deal includes a $533 million equity commitment from the Getty Family and Koch Equity Development, the retirement of senior unsecured notes for $170.2 million in cash, and the conversion of existing equity into 100% ownership for the majority shareholders, taking the company private.
TTM Technologies delivered record Q2 2026 results, beating guidance and raising full-year revenue and EPS outlooks driven by massive AI data center demand and defense growth.
FormFactor entered into a Securities Purchase Agreement with Teradyne, Inc. for a $300 million strategic equity investment via a private placement of 2,234,887 shares of common stock. The transaction is part of a broader technology collaboration aimed at accelerating semiconductor testing for AI, high-performance computing, and advanced packaging applications.
ADC Therapeutics entered into securities purchase agreements for a $86.6 million private placement (PIPE) involving the sale of 12.9 million common shares and 48.1 million pre-funded warrants. The financing included participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. Proceeds will be used to fund ZYNLONTA pipeline studies and extend the company's cash runway into 2029.
IonQ delivered record Q2 revenue of $80.1M, up 287% YoY, while closing the $1.8B Skywater acquisition to become a vertically integrated quantum platform.
TTM Technologies announced a $400 million incremental investment to expand manufacturing capacity across four facilities in China and its facility in Penang, Malaysia. The expansion uses a "rapid-ramp" brownfield approach to scale advanced interconnect technology for AI data center infrastructure and hyperscalers. This investment is in addition to the company's previously disclosed $1.2 billion commitment for the 2025-2029 period.
Humana Partnership with BlackRock, Inc. Worth $2.8B
Humana entered into a new strategic joint venture with BlackRock to manage and operate nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake held by Welsh, Carson, Anderson & Stowe (WCAS) for approximately $2.8 billion, providing Humana with a lower cost of capital and enhanced balance sheet efficiency by removing existing put option liabilities.